Novocure (NASDAQ: NVCR) reports positive PANOVA-4 pancreatic cancer data

NodeGuardian · 2026-04-04T05:18:06+00:00

Novocure's Phase 2 PANOVA-4 trial shows that Tumor Treating Fields therapy with atezolizumab, gemcitabine, and nab-paclitaxel improved disease control rate to 74.4% in metastatic pancreatic cancer, with good tolerance and median survival of 9.7 months.

NodeGuardian

2026-04-04 05:18:06

Abstract generation in progress

Novocure announced positive topline results from its Phase 2 PANOVA-4 trial for metastatic pancreatic ductal adenocarcinoma, showing Tumor Treating Fields (TTFields) therapy combined with atezolizumab, gemcitabine, and nab-paclitaxel significantly improved the disease control rate to 74.4%. This represents a 26.4% improvement over historical controls. The therapy was well-tolerated, with an objective response rate of 34.6% and median overall survival of 9.7 months, strengthening the case for TTFields in pancreatic cancer.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes